Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management

May combine two claims.

Inclisiran is non-immunogenic, with no hypersensitivity reactions or antibody formation observed.

“The non-immunogenic nature of Inclisiran stands as an important advantage since no hypersensitivity reactions or antibody formation have been observed despite the use of protein-based therapeutics [32].”

• cites [32] Bellosta S, Rossi C, Alieva A, Catapano A, Corsini A, Baragetti A. Cholesterol Lowering biotechnological strategies: from monoclonal antibodies to antisense therapies. A pre-clinical perspective review. Cardiovasc Drugs Ther. 2023;37(3):585–98. sourceDisputed

  In the section ‘siRNA to modulate PCSK9 expression’ (page unavailable), the review reports that anti-inclisiran antibodies occurred in about 2% of treated patients and that symptoms of immune-system activation were rare, not absent. It does not establish whether hypersensitivity reactions occurred, but its antibody finding directly contradicts the claim that no antibody formation was observed. (LLM, conf=0.90)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured

May combine two claims.

Inclisiran improved multiple lipid parameters including non-HDL-C, apoB, triglycerides, and lipoprotein(a) in addition to LDL-C.

“Inclisiran improved multiple lipid parameters including non-HDL-C, apoB, triglycerides and lipoprotein(a) in addition to LDL-C which makes it beneficial for complete lipid management [39, 43, 49].”

• cites [39] Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous Familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520–30. sourceSupported
• cites [43] Raal F, Durst R, Bi R, Talloczy Z, Maheux P, Lesogor A, et al. Efficacy, safety, and tolerability of inclisiran in patients with homozygous Familial hypercholesterolemia: results from the ORION-5 randomized clinical trial. Circulation. 2024;149(5):354–62. sourceDisputed

  In ORION-5 patients with homozygous familial hypercholesterolemia, the Results (Primary End Point) found no statistically significant LDL-C benefit over placebo. The Results (Other Secondary End Points) likewise found no statistically significant differences for apoB, non-HDL-C, or lipoprotein(a) at any time point. These findings run contrary to the unqualified claim that inclisiran improved those lipid parameters; the cited passages do not report a triglyceride benefit. (LLM, conf=0.90)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured
• cites [49] Reijman MD, Schweizer A, Peterson AL, Bruckert E, Stratz C, Defesche JC, et al. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous Familial hypercholesterolaemia. Eur J Prev Cardiol. 2022;29(9):1361–8. sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Statins provide consistent cardiovascular benefits and all-cause mortality reduction.

“The Heart Protection Study and Cholesterol Treatment Trialists’ Collaborators meta-analyses have demonstrated that statins provide consistent cardiovascular benefits and all-cause mortality reduction for patients [6, 7].”

• cites [6] Ray KK, Seshasai SRK, Erqou S, Sever P, Jukema JW, Ford I, Sattar N. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65 229 participants. Arch Intern Med. 2010;170(12):1024–31. sourceNot checked — no full text of the source
• cites [7] Group HPSC. Effects on 11-year mortality and morbidity of Lowering LDL cholesterol with Simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial. Lancet. 2011;378(9808):2013–20. sourceSupported

May combine two claims.

Inclisiran's chemical structure includes a GalNAc-triantennary N-acetylgalactosamine linked to a double-stranded siRNA, enabling hepatocyte-specific uptake through ASGPR.

“The chemical structure of Inclisiran includes a GalNAc-triantennary N-acetylgalactosamine linked to a double-stranded siRNA which enables hepatocyte-specific uptake through asialoglycoprotein receptors (ASGPR) [15, 16].”

• cites [15] Wilkinson MJ, Bajaj A, Brousseau ME, Taub PR. Harnessing RNA interference for cholesterol lowering: the bench-to‐bedside story of inclisiran. J Am Heart Association. 2024;13(6):e032031. sourceSupported
• cites [16] Ramírez-Cortés F, Ménová P. Hepatocyte targeting via the Asialoglycoprotein receptor. RSC Med Chem. 2025;16(2):525–44. sourcePartly supported

  The paper places inclisiran in its GalNAc–siRNA conjugates section and states that these conjugates bind ASGPR and undergo cellular uptake. The section mentions a classical triantennary architecture, but the passages do not specify that inclisiran itself has that architecture. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

PCSK9 production remains suppressed over time because inclisiran causes long-term reduction of the protein source, leading to increased LDLR expression and low blood LDL cholesterol.

“PCSK9 production remains suppressed throughout time because the source of the protein receives long-term reduction which leads to increased LDLR expression that keeps LDL cholesterol levels in the blood low [18, 19].”

• cites [18] Stoekenbroek RM, Lambert G, Cariou B, Hovingh GK. Inhibiting PCSK9—biology beyond LDL control. Nat Reviews Endocrinol. 2019;15(1):52–62. sourceCould not verify

  The available passages consist of the title and bibliographic metadata (including passages labeled Abstract, with no page number). Searches for inclisiran, sustained PCSK9 suppression, LDL receptors, and LDL cholesterol found no passage describing the claimed mechanism or duration of effect. The title alone cannot establish the claim. (LLM, conf=0.75)

  Experimental — accuracy not yet measured
• cites [19] Xia X-d, Peng Z-s, Gu H-m, Wang M, Wang G-q. Zhang D-w. Regulation of PCSK9 expression and function: mechanisms and therapeutic implications. Front Cardiovasc Med. 2021;8:764038. sourcePartly supported

  The PCSK9 Function section says inclisiran targets PCSK9 mRNA and reduces its expression, while the Conclusion reports LDL-cholesterol reductions with twice-yearly injections. The paper explains that PCSK9 promotes LDLR degradation, so inhibiting it can preserve LDLR, but it does not establish increased LDLR expression or suppression throughout time without continued dosing. Page numbers were not available in our copy. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

May combine two claims.

ORION-9 examined HeFH patients because this condition leads to extreme LDL-C elevation and increases risk of early ASCVD.

“The ORION-9 clinical study examined heterozygous familial hypercholesterolemia (HeFH) patients because this condition leads to extreme LDL-C elevation and increases the risk of early atherosclerotic cardiovascular disease (ASCVD) [27].”

• cites [27] Koenig W, Ray KK, Kallend DG, Landmesser U, Leiter LA, Schwartz GG, Wright RS, Garcia Conde L, Jaros M, Raal FJ. Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials. European Heart Journal. 2021 Oct 1;42(Supplement_1):ehab724–2026. https://doi.org/10.1093/eurheartj/ehab724.2026. sourcePartly supported

  The Methods section lists patients with HeFH among those drawn from ORION-9, ORION-10, and ORION-11, supporting the connection between ORION-9 and HeFH, though it does not assign each patient group to a specific trial. It does not say that HeFH causes extreme LDL-C elevation or increases the risk of early ASCVD, or give that as the reason ORION-9 examined these patients. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

May combine two claims.

The therapeutic gap in lipid lowering is contributed to by statin intolerance or resistance, poor medication adherence, and residual cardiovascular risk in patients who meet LDL-C targets.

“Several obstacles contribute to the therapeutic gap including statin intolerance or resistance and poor medication adherence and remaining cardiovascular risk for patients who meet their LDL-C targets.”

• cites [8] Barrios V, Pintó X, Escobar C, Varona JF, Gámez JM. Real-world attainment of low-density lipoprotein cholesterol goals in patients at high risk of cardiovascular disease treated with high-intensity statins: the TERESA study. J Clin Med. 2023;12(9):3187. sourcePartly supported

  The Discussion (page unavailable) says statin adverse effects can lead to non-compliance, and its limitations section notes that adherence matters for LDL-C goal attainment, though this study did not have compliance data. The paper does not establish statin resistance as an obstacle or assess remaining cardiovascular risk in patients who meet LDL-C targets. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

LDL-C reduction is an essential component of preventive cardiology practice.

“thus establishing LDL-C reduction as an essential component of preventive cardiology practice [4, 5].”

• cites [4] Mak YH, Chua F, Koh XH, Tan VH, Lee ZH, Lam A, et al. Low-density lipoprotein cholesterol goal attainment and mortality in ischaemic heart disease: a two-year observational study. Singapore Med J. 2025;66(3):154–62. sourceSupported
• cites [5] Tall AR, Thomas DG, Gonzalez-Cabodevilla AG, Goldberg IJ. Addressing dyslipidemic risk beyond LDL-cholesterol. The Journal of clinical investigation. 2022;132(1). https://doi.org/10.1172/JCI148559. sourceSupported

May combine two claims.

Clinical trials demonstrate that LDL-C levels decrease by 50% and maintain this reduction for at least 18 months of treatment.

“Clinical trials demonstrate that LDL-C levels decrease by 50% and maintain this reduction for at least 18 months of treatment [25, 26].”

• cites [25] Ray KK, Stoekenbroek RM, Kallend D, Nishikido T, Leiter LA, Landmesser U, et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. JAMA Cardiol. 2019;4(11):1067–75. sourcePartly supported

  The Conclusions (page not available) state that a 50% LDL-C reduction can be maintained for at least 6 months after two 300-mg doses of inclisiran. The trial followed participants for a maximum of 360 days, so it does not demonstrate that the reduction persists for at least 18 months. (LLM, conf=0.92)

  Experimental — accuracy not yet measured
• cites [26] Albosta MS, Grant JK, Taub P, Blumenthal RS, Martin SS, Michos ED. Inclisiran: a new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease. Vascular health and risk management. 2023:421–31. https://doi.org/10.2147/VHRM.S338424. sourceSupported

May combine two claims.

PCSK9 monoclonal antibodies used in FOURIER and ODYSSEY OUTCOMES decreased LDL-C levels and reduced cardiovascular events.

“PCSK9 monoclonal antibodies used in FOURIER and ODYSSEY OUTCOMES clinical trials proved their ability to decrease LDL-C levels and reduce cardiovascular events [13].”

• cites [13] Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168(5):682–9. e1. sourcePartly supported

  The Abstract (page not provided) says PCSK9 antibodies can substantially reduce LDL-C and identifies alirocumab as the antibody being tested in ODYSSEY Outcomes. It describes cardiovascular-event reduction as a hypothesis the trial will test, not a proven result. The cited paper provides no FOURIER trial result. (LLM, conf=0.90)

  Experimental — accuracy not yet measured

May combine two claims.

The ORION-10 and ORION-11 trials showed that patients achieved LDL-C decreases of 52.3% and 49.9% at Day 510.

“The trials showed that patients achieved LDL-C decreases of 52.3% and 49.9% at Day 510 [44].”

• cites [44] Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–19. sourcePartly supported

  The Results (p. 1) give 52.3% and 49.9% reductions at day 510 for ORION-10 and ORION-11. The Efficacy section (p. 5) clarifies that these are differences versus placebo, not the decreases observed in patients receiving inclisiran, which were 51.3% and 45.8%, respectively. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

Methodological quality of included randomized controlled trials was assessed using the Cochrane Risk of Bias Tool 2.0 (RoB 2).

“Methodological quality of included randomized controlled trials was conducted using the Cochrane Risk of Bias Tool 2.0 (RoB 2) which examines five domains consisting of randomization process deviations from intended interventions missing outcome data measurement of outcomes and selection of reported results [36, 37].”

• cites [36] Satyam SM, El-Tanani M, Patni MA, Rehman A, Wali AF, Rangraze IR, et al. Repurposing anthelmintic drugs for COVID-19 treatment: A comprehensive meta-analysis of randomized clinical trials on Ivermectin and Mebendazole. Antibiotics. 2025;14(5):459. sourceSupported
• cites [37] Minozzi S, Cinquini M, Gianola S, Gonzalez-Lorenzo M, Banzi R. The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application. J Clin Epidemiol. 2020;126:37–44. sourceNot checked — no full text of the source

May combine two claims.

ORION-9, −10 and −11 combined in a pooled analysis (n = 3,658) demonstrated LDL-C reductions of 47.6% to 51.9% between different glycemic groups and 48.8% to 54.4% between different BMI groups.

“ORION-9, −10 and − 11 combined in a pooled analysis (n = 3,658) demonstrated LDL-C reductions of 47.6% to 51.9% between different glycemic groups including normoglycemia, prediabetes and diabetes and 48.8% to 54.4% between different BMI groups from underweight (< 25 kg/m²) to obesity (≥ 35 kg/m²) [40].”

• cites [40] Leiter LA, Raal FJ, Schwartz GG, Koenig W, Ray KK, Landmesser U, et al. Inclisiran in individuals with diabetes or obesity: post hoc pooled analyses of the ORION-9, ORION‐10 and ORION‐11 phase 3 randomized trials. Diabetes Obes Metabolism. 2024;26(8):3223–37. sourcePartly supported

  The Study population section reports a pooled sample of 3,658, and Figure 1 reports the cited Day 510 LDL-C reduction ranges across glycaemic and BMI groups. However, the citing sentence calls the <25 kg/m² BMI group “underweight”; the paper classifies it as “normal” (Population section). (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

Long-term studies have established inclisiran as a fundamental drug for lipid management due to its ability to ensure high patient adherence and long-term LDL-C control.

“Long-term studies have established inclisiran as a fundamental drug for lipid management due to its ability to ensure high patient adherence and long-term LDL-C control [47, 48].”

• cites [47] Barkas F, Ray K. An update on inclisiran for the treatment of elevated LDL cholesterol. Expert Opin Pharmacother. 2024;25(4):349–58. sourceNot checked — no full text of the source
• cites [48] Agnello F, Ingala S, Laterra G, Scalia L, Barbanti M. Novel and emerging LDL-C Lowering strategies: a new era of dyslipidemia management. J Clin Med. 2024;13(5):1251. sourcePartly supported

  Section 4.2 reports sustained LDL-C reductions in a four-year inclisiran extension study, supporting the long-term control claim. But section 6 describes improved medication adherence as a potential advantage of twice-yearly dosing, not an established ability to ensure high adherence; the paper also does not establish inclisiran as a fundamental drug. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

• AssumptionRests on an assumption: Reducing LDL-C levels reduces cardiovascular risk.

May combine two claims.

The Japanese patient population in ORION-15 showed a 65.3% LDL-C decrease and ORION-14 patients in China experienced a 74.9% LDL-C reduction at Day 90 following their first 300 mg dose.

“The Japanese patient population in ORION-15 showed a 65.3% LDL-C decrease and ORION-14 patients in China experienced a 74.9% LDL-C reduction at Day 90 following their first 300 mg dose [24, 46].”

• cites [24] Luo Z, Huang Z, Sun F, Guo F, Wang Y, Kao S, et al. The clinical effects of inclisiran, a first-in-class LDL-C Lowering SiRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. J Clin Lipidol. 2023;17(3):392–400. sourceNot checked — no full text of the source
• cites [46] Yamashita S, Kiyosue A, Maheux P, Mena-Madrazo J, Lesogor A, Shao Q, et al. Efficacy, safety, and pharmacokinetics of inclisiran in Japanese patients: results from ORION-15. J Atheroscler Thromb. 2024;31(6):876–903. sourceSupported

May combine two claims.

The ORION-1 trial showed that inclisiran reduced non-HDL cholesterol by up to 46%, apolipoprotein B by up to 41%, VLDL cholesterol by 24%, lipoprotein(a) slightly, and triglycerides by 13-14%, while increasing HDL cholesterol by a small amount.

“The ORION-1 trial showed that inclisiran reduced non-HDL cholesterol by up to 46%, apolipoprotein B by up to 41% and very-low-density lipoprotein cholesterol by 24% and it reduced lipoprotein(a) slightly and triglycerides by 13–14% while increasing HDL cholesterol by a small amount [50].”

• cites [50] Ray KK, Stoekenbroek RM, Kallend D, Leiter LA, Landmesser U, Wright RS, et al. Effect of an SiRNA therapeutic targeting PCSK9 on atherogenic lipoproteins: prespecified secondary end points in ORION 1. Circulation. 2018;138(13):1304–16. sourceSupported

May combine two claims.

Inclisiran proved effective for all ethnicities, BMI categories, glycemic states, and worldwide locations including South Africa, China, and Japan.

“Inclisiran proved effective for all ethnicities and BMI categories as well as glycemic states and worldwide locations including South Africa, China and Japan thus proving its worldwide application [42].”

• cites [42] Wright RS, Raal FJ, Koenig W, Landmesser U, Leiter LA, Vikarunnessa S, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovascular Res. 2024;120(12):1400–10. sourcePartly supported

  The Results (Study outcomes; page unavailable) report substantial LDL-C lowering overall. Table 1 records participants’ race, BMI and diabetes status, but the paper does not report efficacy across all ethnicities, BMI categories or glycemic states. The Methods (Study design and participants; page unavailable) place ORION-8 centres in Europe, North America and Africa, not China or Japan, so the claimed worldwide applicability is not established by this trial. (LLM, conf=0.89)

  Experimental — accuracy not yet measured

May combine two claims.

The 50-60 mg/dL reduction in LDL-C from inclisiran administration indicates that patients may experience a 25-30% relative risk reduction in ASCVD events comparable to what PCSK9 monoclonal antibodies provide.

“The 50–60 mg/dL reduction in LDL-C from inclisiran administration indicates that patients may experience a 25–30% relative risk reduction in ASCVD events comparable to what PCSK9 monoclonal antibodies provide [26].”

• cites [26] Albosta MS, Grant JK, Taub P, Blumenthal RS, Martin SS, Michos ED. Inclisiran: a new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease. Vascular health and risk management. 2023:421–31. https://doi.org/10.2147/VHRM.S338424. sourcePartly supported

  The Clinical Efficacy and Safety section reports roughly 50% LDL-C lowering with inclisiran, and Cardiovascular Outcomes Data reports a preliminary pooled analysis with a MACE hazard ratio of 0.75. But the Introduction reports a 15% relative risk reduction for each PCSK9 monoclonal antibody—not 25–30%—and the Conclusion says dedicated cardiovascular outcomes results for inclisiran were not yet available. The claimed 50–60 mg/dL reduction and comparable 25–30% event-risk reduction are therefore not established by this review. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

In the ORION-8 long-term extension study, inclisiran achieved a 49.4% reduction of LDL-C during 3.7 years of median follow-up with no signs of tachyphylaxis.

“During the ORION-8 long-term extension study inclisiran achieved a 49.4% reduction of LDL-C during 3.7 years of median follow-up with no signs of tachyphylaxis [42].”

• cites [42] Wright RS, Raal FJ, Koenig W, Landmesser U, Leiter LA, Vikarunnessa S, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovascular Res. 2024;120(12):1400–10. sourcePartly supported

  The Results (Study outcomes; page unavailable) report a mean 49.4% LDL-C reduction at end-of-study, and the Discussion (Study limitations; page unavailable) describes sustained lowering without evidence of waning efficacy. The paper calls 3.7 years the mean cumulative treatment exposure, not the median follow-up, so that qualifier is unsupported. (LLM, conf=0.92)

  Experimental — accuracy not yet measured

May combine two claims.

Long-term results from ORION-8 indicated that twice-yearly dosing maintained LDL-C reductions for 6.8 years, allowing more than 78% of patients to meet guideline standards.

“Long-term results from ORION-8 indicated that the twice-yearly dosing-maintained LDL-C reductions for 6.8 years which allowed more than 78% of patients to meet guideline standards.”

• cites [42] Wright RS, Raal FJ, Koenig W, Landmesser U, Leiter LA, Vikarunnessa S, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovascular Res. 2024;120(12):1400–10. sourceSupported

May combine two claims.

The analysis of 11 RCTs for quantitative synthesis included more than 13,000 participants and showed inclisiran produces significant LDL-C reduction versus placebo treatment.

“The analysis of 11 RCTs for quantitative synthesis included more than 13,000 participants showed inclisiran produces significant LDL-C reduction versus placebo treatment [24, 25, 38–44, 46, 49].”

• cites [24] Luo Z, Huang Z, Sun F, Guo F, Wang Y, Kao S, et al. The clinical effects of inclisiran, a first-in-class LDL-C Lowering SiRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. J Clin Lipidol. 2023;17(3):392–400. sourceNot checked — no full text of the source
• cites [25] Ray KK, Stoekenbroek RM, Kallend D, Nishikido T, Leiter LA, Landmesser U, et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. JAMA Cardiol. 2019;4(11):1067–75. sourcePartly supported

  The Abstract reports that inclisiran significantly reduced LDL-C in the placebo-controlled ORION-1 trial (P < .001 between groups). But this paper is a prespecified analysis of one trial with 501 participants, not a quantitative synthesis of 11 RCTs involving more than 13,000 participants. (LLM, conf=0.91)

  Experimental — accuracy not yet measured
• cites [38] Leiter LA, Teoh H, Kallend D, Wright RS, Landmesser U, Wijngaard PL, et al. Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status: the ORION-1 randomized clinical trial. Diabetes Care. 2019;42(1):173–6. sourcePartly supported

  The Abstract and Results describe ORION-1, a placebo-controlled trial that randomized 501 participants and found significant LDL-C reductions with inclisiran. This paper can support the trial’s contribution to the cited synthesis, but it does not report an analysis of 11 RCTs or more than 13,000 participants. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [39] Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous Familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520–30. sourcePartly supported

  The Primary End Points (p. 4) report significantly lower LDL cholesterol with inclisiran than with placebo (P<0.001). But the Trial Population (p. 4) describes one trial with 482 randomized patients; this paper does not report an analysis of 11 RCTs involving more than 13,000 participants. (LLM, conf=0.90)

  Experimental — accuracy not yet measured
• cites [40] Leiter LA, Raal FJ, Schwartz GG, Koenig W, Ray KK, Landmesser U, et al. Inclisiran in individuals with diabetes or obesity: post hoc pooled analyses of the ORION-9, ORION‐10 and ORION‐11 phase 3 randomized trials. Diabetes Obes Metabolism. 2024;26(8):3223–37. sourcePartly supported

  The Key secondary endpoints section reports lower LDL cholesterol with inclisiran than placebo, with p < 0.001 across the reported glycaemic and BMI strata. But the Methods and Discussion identify this paper as a pooled analysis of three Phase 3 trials, not an analysis of 11 RCTs involving more than 13,000 participants. Page numbers are not available in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [41] Raal F, Abelson M, Blignaut S, Burgess L, Coetzer S, Ebrahim I, et al. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials. South Afr Med J. 2022;112(6):426–32. sourcePartly supported

  The Co-primary endpoints section reports a significant LDL-C reduction with inclisiran versus placebo (p<0.0001). However, the Trial population section describes 298 South African participants, and the Trial design and oversight section identifies three ORION trials; this paper does not report a quantitative synthesis of 11 RCTs involving more than 13,000 participants. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [42] Wright RS, Raal FJ, Koenig W, Landmesser U, Leiter LA, Vikarunnessa S, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovascular Res. 2024;120(12):1400–10. sourcePartly supported

  The Introduction reports that a pooled analysis of three placebo-controlled trials found approximately 51% lower LDL-C with inclisiran than with placebo. But ORION-8 is an open-label extension of 3,274 patients; this paper does not report a quantitative synthesis of 11 RCTs involving more than 13,000 participants (Methods, Statistical analysis; Results, Demographic and clinical characteristics). (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [43] Raal F, Durst R, Bi R, Talloczy Z, Maheux P, Lesogor A, et al. Efficacy, safety, and tolerability of inclisiran in patients with homozygous Familial hypercholesterolemia: results from the ORION-5 randomized clinical trial. Circulation. 2024;149(5):354–62. sourcePartly supported

  The Methods identify ORION-5 as a randomized, placebo-controlled inclisiran trial in 56 patients, so it supports citing this paper as one trial relevant to the synthesis. It does not report an analysis of 11 RCTs or more than 13,000 participants. Its Results > Primary End Point instead found no statistically significant LDL-C difference between inclisiran and placebo (P=0.90); that individual result does not establish or rule out the claimed pooled result. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [44] Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–19. sourceSupported
• cites [46] Yamashita S, Kiyosue A, Maheux P, Mena-Madrazo J, Lesogor A, Shao Q, et al. Efficacy, safety, and pharmacokinetics of inclisiran in Japanese patients: results from ORION-15. J Atheroscler Thromb. 2024;31(6):876–903. sourceSupported

May combine two claims.

Even in the rare presence of anti-drug antibodies, effective PCSK9 mRNA silencing and robust LDL-C lowering are maintained.

“As a result, even in the rare presence of ADAs, effective PCSK9 mRNA silencing and robust LDL-C lowering are maintained [32].”

• cites [32] Bellosta S, Rossi C, Alieva A, Catapano A, Corsini A, Baragetti A. Cholesterol Lowering biotechnological strategies: from monoclonal antibodies to antisense therapies. A pre-clinical perspective review. Cardiovasc Drugs Ther. 2023;37(3):585–98. sourceSupported

May combine two claims.

The lipid trials demonstrate positive effects on apolipoprotein B (apoB) levels together with non-HDL cholesterol and lipoprotein(a) as well as LDL-C reduction.

“The lipid trials demonstrate positive effects on apolipoprotein B (apoB) levels together with non-HDL cholesterol and lipoprotein(a) as well as LDL-C reduction [45, 59].”

• cites [45] Ray KK, Kallend D, Leiter LA, Raal FJ, Koenig W, Jaros MJ, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022;43(48):5047–57. sourceSupported
• cites [59] Wójcik C. Emerging lipid Lowering agents targeting LDL cholesterol. Postgrad Med. 2020;132(5):433–40. sourceNot checked — no full text of the source

May combine two claims.

Inclisiran demonstrated fewer muscle-related adverse events (11.9% vs. 19.2%; OR 0.57, P < 0.001) and favorable effects on pain-related quality-of-life scores, with no new safety signals identified.

“Inclisiran also demonstrated fewer muscle-related adverse events (11.9% vs. 19.2%; OR 0.57, P < 0.001) and favorable effects on pain-related quality-of-life scores, with no new safety signals identified.”

• cites [35] Landmesser U, Laufs U, Schatz U, Winzer EB, Nowak B, Kassner U, Gouni-Berthold I, Esteban A, Lubyayi L, Krueger A, Hentschke C. Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-difference trial. European Heart Journal. 2025:ehaf685. https://doi.org/10.1093/eurheartj/ehaf685. sourceSupported

May combine two claims.

Long-interval therapies such as inclisiran, administered twice yearly, may contribute to more stable LDL-C control, potentially enhancing cardiovascular protection beyond absolute LDL-C reduction.

“Long-interval therapies such as inclisiran, administered twice yearly, may contribute to more stable LDL-C control, potentially enhancing cardiovascular protection beyond absolute LDL-C reduction [21].”

• cites [21] Cesaro A, Acerbo V, Scialla F, Zito A, Porcelli G, Panico D, Argenziano G, Iaria D, Monaco MG, De Sio V, Gragnano F. Reduction of Visit-to-Visit LDL-C Intraindividual Variability in Patients Treated with PCSK9 Inhibitors and Inclisiran Versus Standard Lipid-Lowering Therapy. Journal of Clinical Lipidology. 2025. https://doi.org/10.1016/j.jacl.2025.10.066. sourceSupported

May combine two claims.

In many cases antibodies recognize the GalNAc moiety or otherwise non-neutralizing epitopes, and in-vitro neutralization does not necessarily predict in-vivo functional loss.

“In many cases antibodies recognize the GalNAc moiety or otherwise non-neutralizing epitopes; in-vitro neutralization does not necessarily predict in-vivo functional loss.”

• cites [53] Ballman KK, Peek VL, Sloan JH, Li J, Konrad RJ, Wen Y. Cross-Reactive polyclonal antibodies Raised against GalNAc-Conjugated SiRNA recognize mostly the GalNAc moiety. AAPS J. 2024;26(3):41. sourceNot checked — no full text of the source
• cites [54] Pratt KP. Anti-drug antibodies: emerging approaches to predict, reduce or reverse biotherapeutic immunogenicity. Antibodies. 2018;7(2):19. sourcePartly supported

  The Introduction (page unavailable) says non-neutralizing anti-drug antibodies can reduce efficacy by affecting clearance, pharmacodynamics, or pharmacokinetics. It does not say that antibodies commonly recognize GalNAc, and it does not compare in-vitro neutralization results with in-vivo functional loss. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

Inclisiran is a safe and effective treatment for lipid reduction among diverse patient groups.

“The research findings demonstrate that Inclisiran functions as a safe and effective treatment for lipid reduction among diverse patient groups [70].”

• cites [70] Ray KK, Troquay RP, Visseren FL, Leiter LA, Wright RS, Vikarunnessa S, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11(2):109–19. sourcePartly supported

  The paper’s conclusion (Table 4 section; page not provided) says inclisiran was well tolerated and produced sustained LDL-cholesterol reductions over four years. The eligibility criteria and Results describe patients with ASCVD or at high risk of cardiovascular disease, but the copy does not establish safety and efficacy across diverse patient groups broadly; 94% of participants were White. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

May combine two claims.

Ezetimibe provides additional LDL-C reduction of 15-20% but is often insufficient for high-risk individuals.

“Additional LDL-C reduction from ezetimibe therapy amounts to 15–20% but it often proves insufficient to meet the needs of individuals at high risk [77].”

• cites [77] Soran H, Dent R, Durrington P. Evidence-based goals in LDL-C reduction. Clin Res Cardiol. 2017;106(4):237–48. sourcePartly supported

  The Interventional studies section (page not provided) reports that adding ezetimibe lowered LDL-C by around 24%, not 15–20%. The Abstract notes that some patients have high LDL-C despite maximum statin and ezetimibe therapy, supporting the point that this combination can be insufficient, but it does not establish how often this occurs among high-risk individuals. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

Many patients stop taking daily statin medications or PCSK9 antibody injections irregularly, reducing their ability to prevent cardiovascular diseases.

“Clinical observations demonstrate that numerous patients stop taking their daily statin medications or PCSK9 antibody injections irregularly which reduces their ability to prevent cardiovascular diseases [44, 80].”

• cites [44] Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–19. sourcePartly supported

  The Discussion (p. 11) says poor statin adherence is associated with less LDL-cholesterol reduction and a higher risk of cardiovascular events. It does not report that patients take PCSK9 antibody injections irregularly or that missed injections reduce cardiovascular prevention; the paper studies inclisiran, a different treatment. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [80] Cicero AF, Fogacci F, Zambon A, Toth PP, Borghi C. Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies. Am Heart J Plus: Cardiol Res Pract. 2022;13:100127. sourcePartly supported

  The Discussion says poor long-term adherence can prevent patients from reaching LDL-C goals and contribute to residual cardiovascular risk. It does not report clinical observations that numerous patients stop daily statins or take PCSK9 antibody injections irregularly; it describes adherence to PCSK9 inhibitors as already acceptable. Page numbers are unavailable in our copy. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

May combine two claims.

Statins are effective, safe, and affordable but fail to meet LDL-C goals or are poorly tolerated by some patients.

“The primary choice of statins works well due to their effectiveness and safety as well as affordability, but they fail to meet LDL-C goals or are poorly tolerated by patients [74–76].”

• cites [74] McKenney JM. Optimizing LDL-C Lowering with Statins. Am J Ther. 2004;11(1):54–9. sourceNot checked — no full text of the source
• cites [75] Krähenbühl S, Pavik-Mezzour I, von Eckardstein A. Unmet needs in LDL-C lowering: when Statins won’t do! Drugs. 2016;76(12):1175–90. sourcePartly supported

  The Abstract describes statins as effective and generally well tolerated, while noting adverse effects and patients for whom statins do not lower LDL-C sufficiently. The Introduction likewise says some patients do not reach LDL-C targets or cannot adhere because of adverse effects. The passages do not establish the claim that statins are affordable. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [76] Banach M, Penson PE. Statins and LDL-C in secondary prevention—So much progress, so Far to go. JAMA Netw Open. 2020;3(11):e2025675–e. sourceSupported

May combine two claims.

Rare hepatotoxicity, myopathy, or renal toxicity events were observed, and no concerning trends emerged from routine laboratory tests.

“Rare hepatotoxicity or myopathy or renal toxicity events were observed and no concerning trends emerged from routine laboratory tests [82, 83].”

• cites [82] Zou D, Hu Q, Liu Y, Yu L. Post-marketing pharmacovigilance study of inclisiran: mining and analyzing adverse event data from the FDA adverse event reporting system database. Int J Clin Pharm. 2024;46(6):1419–26. sourceNot checked — no full text of the source
• cites [83] Dyrbuś K, Gąsior M, Penson P, Ray KK, Banach M. Inclisiran—new hope in the management of lipid disorders? J Clin Lipidol. 2020;14(1):16–27. sourcePartly supported

  The Drug safety section (page not provided) reports one asymptomatic elevation of liver enzymes, which the cited study’s authors associated with concurrent atorvastatin, and lists musculoskeletal pain among reported adverse effects. It does not identify those events as hepatotoxicity or myopathy, report renal toxicity events, or assess trends across routine laboratory tests. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

PCSK9 inhibitors are effective but frequent injections and high price restrict their acceptance by healthcare providers.

“PCSK9 inhibitors have proven their effectiveness but their frequent injections and expensive price have restricted their acceptance by healthcare providers [78, 79].”

• cites [78] Lee GA, Durante A, Baker EE, Vellone E, Caggianelli G, Dellafiore F, et al. Healthcare professionals’ perspectives on the use of PCSK9 inhibitors in cardiovascular disease: an in-depth qualitative study. Eur J Cardiovasc Nurs. 2024;23(8):919–24. sourcePartly supported

  The Introduction (p. 2) describes PCSK9 inhibitors as effective and says they require regular lifelong injections. The paper discusses barriers to prescribing, but the passages found do not say that injection frequency or high price restricted healthcare providers’ acceptance; its Theme 4 (p. 4) instead identifies guidance and organizational barriers. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [79] Navar AM, Taylor B, Mulder H, Fievitz E, Monda KL, Fievitz A, et al. Association of prior authorization and out-of-pocket costs with patient access to PCSK9 inhibitor therapy. JAMA Cardiol. 2017;2(11):1217–25. sourcePartly supported

  The Discussion reports that trial data demonstrated PCSK9 inhibitor effectiveness, and the Conclusions link high cost to prior authorization, high copays, and reduced patient access. The paper does not say that frequent injections or price restricted acceptance by healthcare providers; it examines whether patients received prescriptions their providers had already written. No page numbers are available in our copy. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

May combine two claims.

The siRNA delivery platform eliminates the chance of immune responses that affect protein-based medications because no anti-drug antibodies developed in trial participants.

“The siRNA delivery platform eliminates the chance of immune responses which affect protein-based medications because no anti-drug antibodies (ADAs) developed in trial participants [53, 54].”

• cites [53] Ballman KK, Peek VL, Sloan JH, Li J, Konrad RJ, Wen Y. Cross-Reactive polyclonal antibodies Raised against GalNAc-Conjugated SiRNA recognize mostly the GalNAc moiety. AAPS J. 2024;26(3):41. sourceNot checked — no full text of the source
• cites [54] Pratt KP. Anti-drug antibodies: emerging approaches to predict, reduce or reverse biotherapeutic immunogenicity. Antibodies. 2018;7(2):19. sourcePartly supported

  The Introduction states that protein-based drugs can elicit anti-drug antibodies that reduce efficacy. It does not discuss an siRNA delivery-platform trial, report that no participants developed ADAs, or establish that the platform eliminates the chance of an immune response. (LLM, conf=0.81)

  Experimental — accuracy not yet measured

May combine two claims.

Patients with receptor-negative HoFH derive minimal benefit from PCSK9-targeted therapy, whereas receptor-defective HoFH and HeFH patients exhibit clinically meaningful LDL-C reductions.

“Patients with receptor-negative HoFH derive minimal benefit from PCSK9-targeted therapy, whereas receptor-defective HoFH and heterozygous FH (HeFH) patients exhibit clinically meaningful LDL-C reductions [84].”

• cites [84] Rosenson RS, Hegele RA, Fazio S, Cannon CP. The evolving future of PCSK9 inhibitors. J Am Coll Cardiol. 2018;72(3):314–29. sourceSupported

May combine two claims.

The most common adverse event was injection-site reactions affecting 5-17% of patients across studies, but these were mild to moderate and short-lived with minimal treatment discontinuation.

“The most common adverse event was injection-site reactions affecting 5–17% of patients in different studies but these reactions were mild to moderate and short-lived with minimal need to stop treatment [15, 81].”

• cites [15] Wilkinson MJ, Bajaj A, Brousseau ME, Taub PR. Harnessing RNA interference for cholesterol lowering: the bench-to‐bedside story of inclisiran. J Am Heart Association. 2024;13(6):e032031. sourcePartly supported

  The Clinical Development section reports injection-site adverse events in 5% of inclisiran recipients and says they were mostly mild, with none severe or persistent. The Factors to Consider section reports rates of 8.2% in pooled phase 3 trials and 5.9% in ORION-8, and describes the reactions as mostly mild and short-lived. Our copy does not substantiate the 17% upper end of the claimed range or say that reactions rarely required treatment discontinuation; page numbers were not provided. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [81] Goga A, Stoffel M. Therapeutic RNA-silencing oligonucleotides in metabolic diseases. Nat Rev Drug Discovery. 2022;21(6):417–39. sourceNot checked — no full text of the source

May combine two claims.

The LDL-C lowering capability of inclisiran reaches approximately 45%, ranking it as one of the strongest lipid-lowering medications but falling short of the 60% reduction seen with PCSK9 monoclonal antibodies evolocumab and alirocumab.

“The LDL-C lowering capability of Inclisiran reaches approximately 45% which ranks it as one of the strongest lipid-lowering medications but falls short of the 60% reduction seen with PCSK9 monoclonal antibodies evolocumab and alirocumab [47, 73].”

• cites [47] Barkas F, Ray K. An update on inclisiran for the treatment of elevated LDL cholesterol. Expert Opin Pharmacother. 2024;25(4):349–58. sourceNot checked — no full text of the source
• cites [73] Ruscica M, Ferri N, Santos RD, Sirtori CR, Corsini A. Lipid Lowering drugs: present status and future developments. Curr Atheroscler Rep. 2021;23(5):17. sourcePartly supported

  The “PCSK9 Inhibition by Silencing RNA” section reports a 44.3% time-averaged LDL-C reduction with inclisiran in ORION-9, supporting the approximately 45% figure. The paper calls inclisiran’s LDL-C-lowering effect powerful, but its “PCSK9 Inhibition by Monoclonal Antibodies” section does not give a 60% LDL-C reduction for evolocumab and alirocumab or establish the claimed potency ranking. Page numbers were not available in our copy. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

Monoclonal antibodies achieve slightly higher LDL-C reductions (~60%) than inclisiran, while inclisiran's twice-yearly dosing may enhance adherence and long-term persistence in real-world settings.

“While mAbs achieve slightly higher LDL-C reductions (~ 60%), inclisiran’s twice-yearly dosing may enhance adherence and long-term persistence in real-world settings.”

• cites [47] Barkas F, Ray K. An update on inclisiran for the treatment of elevated LDL cholesterol. Expert Opin Pharmacother. 2024;25(4):349–58. sourceNot checked — no full text of the source
• cites [73] Ruscica M, Ferri N, Santos RD, Sirtori CR, Corsini A. Lipid Lowering drugs: present status and future developments. Curr Atheroscler Rep. 2021;23(5):17. sourcePartly supported

  The 'PCSK9 Inhibition by Silencing RNA' section (page unavailable) reports roughly 50% LDL-C reductions with inclisiran and dosing every 180 days after the initial doses. The passages do not establish approximately 60% LDL-C reduction with monoclonal antibodies or say that inclisiran's schedule may improve real-world adherence or long-term persistence. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim. May combine two claims.

The systematic review identified 293 studies, removed 146 duplicates, screened 147, excluded 35 for unpublished results, retrieved 112 full texts, excluded 90 for irrelevance or lacking methodology, assessed 22 RCTs, excluded 8 for insufficient data, and included 14 RCTs (11 for quantitative synthesis).

“We initially identified 293 studies. After removing 146 duplicates, 147 studies were screened. Of these, 35 were excluded due to unpublished results which left 112 studies for full-text retrieval. Out of 112 studies, 90 were excluded for reasons such as being irrelevant to the research question or lacking detailed methodology. After assessing 22 published full text randomized clinical trials (RCTs”

May combine two claims.

This research includes 14 RCTs for evaluating the effects of inclisiran on lowering LDL-C levels in a population of over 13,000 participants.

“This research includes 14 RCTs for evaluating the effects of inclisiran on lowering LDL-C levels in a population of over 13,000 participants (Fig. 1).”

May combine two claims.

The ORION-8 trial includes participants from ORION 3, 9, 10 and 11 and delivers the longest duration of clinical data.

“The ORION-8 trial which includes participants from ORION 3, 9, 10 and 11 delivers the longest duration of clinical data.”

May combine two claims.

The pivotal ORION-10 and ORION-11 trials enrolled 3,178 patients who had ASCVD or its risk equivalents and supported the durability of inclisiran results.

“The pivotal ORION-10 and ORION-11 trials supported the durability of inclisiran results since they enrolled 3,178 patients who had ASCVD or its risk equivalents.”

Classified as probably not a substantial claim.

The research evaluated lipid parameter changes from short-term 90-day assessments to extended follow-ups lasting up to 540 days.

“The research evaluated lipid parameter changes from short-term 90-day assessments to extended follow-ups lasting up to 540 days to show immediate and prolonged effects of Inclisiran treatment.”

May combine two claims.

Inclisiran proved safe for long-term use in ORION-8 because only 5.9% of participants experienced mild and short-term injection-site reactions.

“Inclisiran proved to be safe for long-term use in ORION-8 because only 5.9% of participants experienced mild and short-term injection-site reactions.”

May combine two claims.

Inclisiran showed significant LDL-C reductions starting at Day 60 and the effects lasted through all six-month dosing cycles.

“The medication showed significant LDL-C reductions starting at Day 60 and the effects lasted through all six-month dosing cycles thus confirming inclisiran’s capability to minimize both medication load and clinical appointments.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The research incorporated different study sizes, including large ORION-10 and ORION-11 trials with more than 3,000 participants and smaller trials such as ORION-5 and Luo et al.'s study with less than 100 participants.

“The research incorporated different study sizes which included the large ORION-10 and ORION-11 trials with more than 3,000 participants while smaller trials such as ORION-5 and Luo et al.’s study included less than 100 participants.”

Probably not a substantial claim: may not pass S4 (based).

Most clinical trials used the same 284 mg subcutaneous administration of inclisiran on Day 1 and Day 90 followed by six-month maintenance dosing.

“Most clinical trials used the same 284 mg subcutaneous administration of Inclisiran on Day 1 and Day 90 followed by six-month maintenance dosing.”

May combine two claims.

The treatment achieved guideline-recommended LDL-C targets below 70 mg/dL for ASCVD patients and below 100 mg/dL for high-risk patients in 78.4% of participants while maintaining these reductions throughout the entire study duration.

“The treatment achieved guideline-recommended LDL-C targets below 70 mg/dL for ASCVD patients and below 100 mg/dL for high-risk patients in 78.4% of participants while maintaining these reductions throughout the entire study duration.”

May combine two claims.

The absolute reductions in LDL-C were greater in patients who started with higher untreated LDL-C levels and those who were on statin therapy at baseline.

“The absolute reductions in LDL-C were greater in patients who started with higher untreated LDL-C levels and those who were on statin therapy at baseline which suggests an enhanced pharmacodynamic effect between inclisiran and HMG-CoA reductase inhibition.”

May combine two claims.

Most of the weight in the meta-analysis came from ORION-10 and ORION-11 because these trials had the most participants and produced the most accurate measurement of LDL-C reduction, which exceeded 50%.

“Most of the weight in the meta-analysis came from ORION-10 and ORION-11 because these trials had the most participants and produced the most accurate measurement of LDL-C reduction which exceeded 50%.”

May combine two claims.

The therapy showed excellent tolerance because patients only experienced minor injection-site reactions while no signs of systemic inflammation or immunologic adverse effects appeared.

“The therapy showed excellent tolerance because patients only experienced minor injection-site reactions while no signs of systemic inflammation or immunologic adverse effects appeared.”

May combine two claims.

The treatment showed safe outcomes through minimal adverse events and low patient discontinuation rates.

“The treatment showed safe outcomes through minimal adverse events and low patient discontinuation rates.”

May combine two claims.

Subgroup meta-regression analyses demonstrated that both untreated baseline LDL-C levels and statin medication use at baseline modified treatment outcomes.

“Subgroup meta-regression analyses demonstrated that both untreated baseline LDL-C levels and statin medication use at baseline modified treatment outcomes.”

May combine two claims.

The smaller trials demonstrated inclisiran's effectiveness in various ethnic and geographical groups, but their limited sample sizes reduced their contribution to statistical power.

“The smaller trials demonstrated inclisiran’s effectiveness in various ethnic and geographical groups, but their limited sample sizes reduced their contribution to statistical power.”

May combine two claims.

Removing smaller trials ORION-14 and ORION-15 resulted in decreased heterogeneity (I2 reduced to 78.6%) yet did not change the overall summary estimate.

“Removing smaller trials ORION-14 and ORION-15 resulted in decreased heterogeneity (I² reduced to 78.6%) yet did not change the overall summary estimate.”

May combine two claims.

The anti-drug antibodies were neutralizing but did not affect lipid-lowering effectiveness or adverse reactions.

“A total of 5.5% of patients developed anti-drug antibodies which were neutralizing but did not affect lipid-lowering effectiveness or adverse reactions.”

May combine two claims.

The safety data collected from these studies reveal a tolerable safety profile with adverse event rates equivalent to those found in placebo-treated patients.

“The safety data collected from these studies reveal a tolerable safety profile with adverse event rates equivalent to those found in placebo-treated patients.”

May combine two claims.

Results from ORION-14 (China) and ORION-15 (Japan) confirmed the robustness of inclisiran's RNA-silencing mechanism across diverse ethnic populations, with mean PCSK9 reductions of 60-80% after a single 300 mg dose.

“Results from ORION-14 (China) and ORION-15 (Japan) confirmed the robustness of inclisiran’s RNA-silencing mechanism across diverse ethnic populations, with mean PCSK9 reductions of 60–80% after a single 300 mg dose.”

May combine two claims.

PCSK9 protein levels decreased by 60%-80% because inclisiran works through siRNA to block hepatic PCSK9 production.

“PCSK9 protein levels decreased by 60%–80% because inclisiran works through siRNA to block hepatic PCSK9 production.”

May combine two claims.

Our meta-analysis of 14 RCTs including over 13,000 participants demonstrates consistent and clinically meaningful LDL-C reductions of approximately 45% across ASCVD, HeFH, HoFH, and statin-intolerant populations, while confirming a favorable safety profile with adverse event rates comparable to placebo.

“Our meta-analysis of 14 RCTs including over 13,000 participants demonstrates consistent and clinically meaningful LDL-C reductions of approximately 45% across ASCVD, HeFH, HoFH, and statin-intolerant populations, while confirming a favorable safety profile with adverse event rates comparable to placebo.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

Trials such as ORION-9 and ORION-5 demonstrated slightly lower absolute PCSK9 reductions (~60%) reflecting the diminished LDL-receptor activity characteristic of these cohorts.

“Trials such as ORION-9 and ORION-5 demonstrated slightly lower absolute reductions (~ 60%) reflecting the diminished LDL-receptor activity characteristic of these cohorts.”

• AssumptionRests on an assumption: Inclisiran’s LDL-C–lowering mechanism requires residual LDLR activity for LDL clearance.

May combine two claims.

Heterogeneity was negligible (I2 = 0%, τ2 = 0; Q = 3.52, p = 0.83), suggesting consistency across studies.

“Heterogeneity was negligible (I² = 0%, τ² = 0; Q = 3.52, p = 0.83), suggesting consistency across studies.”

May combine two claims.

No significant differences were observed in rates of serious adverse events, hepatic or renal dysfunction, or new-onset diabetes.

“No significant differences were observed in rates of serious adverse events, hepatic or renal dysfunction, or new-onset diabetes.”

May combine two claims.

Approximately 5.5% of participants developed anti-drug antibodies in ORION-1, which were typically low-titer and transient and did not correlate with attenuation of LDL-C reduction.

“Although ~ 5.5% of participants developed anti-drug antibodies in ORION-1, these were typically low-titer and transient and did not correlate with attenuation of LDL-C reduction.”

May combine two claims.

Mild transient reactions at the injection site were the most common adverse events, but no evidence existed for hepatotoxicity, myopathy, or immunogenicity.

“Mild transient reactions at the injection site were the most common adverse events but no evidence existed for hepatotoxicity myopathy or immunogenicity.”

May combine two claims.

The most common adverse event was injection-site reaction (5.0%-7.5%), which was usually mild and self-limited.

“The most common adverse event was injection-site reaction (5.0%–7.5%) which was usually mild and self-limited.”

May combine two claims.

The largest contribution to the overall weight came from ORION-10 and ORION-11, which enrolled over 1,500 and 7,000 participants respectively and provided the most precise estimates of PCSK9 reduction exceeding 80%.

“The largest contribution to the overall weight came from ORION-10 and ORION-11, which enrolled over 1,500 and 7,000 participants respectively and provided the most precise estimates of PCSK9 reduction exceeding 80%.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

Most patients under evaluation had elderly conditions combined with multiple diseases.

“The results demonstrate importance because most patients under evaluation had elderly conditions combined with multiple diseases.”

May combine two claims.

No anti-drug antibodies were detected against the siRNA platform, confirming its low immunogenic nature.

“The absence of detected anti-drug antibodies in the siRNA platform confirms its low immunogenic nature [52].”

• cites [52] Landmesser U, Haghikia A, Leiter LA, Wright RS, Kallend D, Wijngaard P, et al. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. Cardiovascular Res. 2021;117(1):284–91. sourceNot checked — no full text of the source

May combine two claims.

Compiled evidence from 14 randomized controlled trials involving more than 13,000 participants demonstrates a consistent LDL-C reduction of approximately 45%, with a favorable safety and tolerability profile.

“The compiled evidence from 14 randomized controlled trials involving more than 13,000 participants demonstrates a consistent LDL-C reduction of approximately 45%, with a favorable safety and tolerability profile.”

May combine two claims.

The present meta-analysis confirms inclisiran is a potent and durable lipid-lowering agent, achieving substantial LDL-C reductions across diverse patient populations including ASCVD, HeFH and HoFH, statin intolerance, and mixed hyperlipidemia.

“The present meta-analysis confirms that inclisiran is a potent and durable lipid-lowering agent, achieving substantial reductions in LDL-C across diverse patient populations, including those with established atherosclerotic cardiovascular disease (ASCVD), familial hypercholesterolemia (HeFH and HoFH), statin intolerance, and mixed hyperlipidemia.”

Probably not a substantial claim: may not pass S2 (checkable).

These findings support inclisiran's role as a promising addition to current strategies for cardiovascular risk reduction.

“These findings support Inclisiran’s role as a promising addition to current strategies for cardiovascular risk reduction.”

Probably not a substantial claim: may not pass S4 (based). May combine two claims.

Inclisiran's RNA-based mechanism and long-acting profile make it particularly suitable for patients who struggle with adherence or have limited response to traditional lipid-lowering medications.

“Its unique RNA-based mechanism and long-acting profile make it particularly suitable for patients who struggle with adherence or have limited response to traditional lipid-lowering medications.”

• AssumptionRests on an assumption: Monoclonal PCSK9 antibodies require twice-monthly dosing and their high cost limits access.

May combine two claims.

Maximum LDL-C reduction occurs within 30 to 90 days and effects become visible after two weeks of treatment.

“The maximum reduction of LDL-C levels occurs within 30 to 90 days and the effects become visible after two weeks of treatment [24].”

• cites [24] Luo Z, Huang Z, Sun F, Guo F, Wang Y, Kao S, et al. The clinical effects of inclisiran, a first-in-class LDL-C Lowering SiRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. J Clin Lipidol. 2023;17(3):392–400. sourceNot checked — no full text of the source

May combine two claims.

Inclisiran provides a durable, twice-yearly injectable option for lipid management, offering substantial reductions in LDL-C.

“Inclisiran provides a durable, twice-yearly injectable option for lipid management, offering substantial reductions in low-density lipoprotein cholesterol.”

• AssumptionRests on an assumption: Inclisiran is administered subcutaneously on Day 1, Day 90, and every six months thereafter.

May combine two claims.

Internalized inclisiran enters hepatocyte cytoplasm to form RISC, which uses the antisense portion of the siRNA to find matching PCSK9 mRNA sequences for site-specific cleavage and mRNA degradation.

“The internalized Inclisiran enters hepatocyte cytoplasm to form an RNA-induced silencing complex (RISC). RISC utilizes the antisense portion of the siRNA as a guide to find matching sequences on PCSK9 mRNA for site-specific cleavage that results in mRNA degradation [17].”

• cites [17] Tosar JP. Small interfering RNAs (siRNAs). Biotherapeutics: from small to large molecules and cells. Springer; 2024. pp. 149–71.Calzada V, Cerecetto H, Tosar JP, editors. Biotherapeutics: From small to large molecules and cells. Springer Nature; 2025. sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Two reviewers independently conducted risk-of-bias assessments using the RoB-2 tool.

“Two reviewers independently conducted risk-of-bias assessments using the RoB-2 tool.”

May combine two claims.

Variability from differences in trial follow-up duration, inclisiran dosing schedules, and LDL-C measurement time points was addressed by grouping outcomes into standardized prespecified time-point windows (Day 150, Day 180, Day 330), applying DerSimonian-Laird random-effects modeling, and performing sensitivity analyses excluding trials with non-standard assessment intervals.

“Variability arising from differences in trial follow-up duration, inclisiran dosing schedules, and LDL-C measurement time points was addressed by grouping outcomes into standardized prespecified time-point windows (Day 150, Day 180, Day 330), applying DerSimonian–Laird random-effects modeling, and performing sensitivity analyses excluding trials with non-standard assessment intervals.”

May combine two claims.

Inclisiran minimizes both medication load and clinical appointments.

“The medication showed significant LDL-C reductions starting at Day 60 and the effects lasted through all six-month dosing cycles thus confirming inclisiran’s capability to minimize both medication load and clinical appointments.”

Probably not a substantial claim: may not pass S3 (load-bearing).

All data in Table 1 were extracted directly from each trial.

“All the data mentioned in this table were extracted directly from each trial.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The search strategy was developed based on the PRISMA 2020 guidelines to maintain methodological rigor and transparency.

“The search strategy was developed based on the PRISMA 2020 guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) for maintaining methodological rigor and transparency throughout the review process.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The selection process was documented using a PRISMA flow diagram detailing records identified, screened, excluded with reasons, and included in qualitative and quantitative syntheses.

“The selection process was documented using a PRISMA flow diagram that detailed the number of records identified, screened, excluded (with reasons), and included in qualitative and quantitative syntheses.”

Classified as probably not a substantial claim.

Long-term non-parallel extension studies were included only in qualitative narrative synthesis and not in quantitative pooling to avoid structural heterogeneity.

“Long-term non-parallel extension studies (e.g., ORION-8), owing to their open-label design and lack of randomized comparators, were included exclusively in the qualitative narrative synthesis but were not incorporated into quantitative pooling to avoid structural heterogeneity.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Sensitivity analyses excluding homozygous FH trials were conducted to evaluate potential biologically driven heterogeneity.

“Sensitivity analyses excluding homozygous FH trials were conducted to evaluate potential biologically driven heterogeneity.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Data from eligible studies were extracted using a standardized and pilot-tested data extraction form.

“Data from eligible studies were extracted using a standardized and pilot-tested data extraction form developed in Microsoft Excel.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Small-study effects and potential publication bias were evaluated using Egger's regression test, Begg's rank-correlation test, and contour-enhanced funnel plot inspection.

“Small-study effects and potential publication bias were evaluated using Egger’s regression test, Begg’s rank-correlation test, and contour-enhanced funnel plot inspection, ensuring a comprehensive assessment beyond visual asymmetry alone.”

May combine two claims.

The treatment produced meaningful clinical reductions in a subset of patients who maintained receptor function, showing the need for genetic classification in HoFH patients.

“The treatment produced meaningful clinical reductions in a subset of patients who maintained receptor function thus showing the need for genetic classification in HoFH patients.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Phenotype-specific subgroup analyses (ASCVD, HeFH, HoFH) were pre-specified.

“Phenotype-specific subgroup analyses (ASCVD, HeFH, HoFH) were pre-specified.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Discrepancies in data extraction were resolved through consensus discussion, with arbitration by a third senior reviewer when necessary.

“Any discrepancies were resolved through consensus discussion, with arbitration by a third senior reviewer when necessary to ensure accuracy and reduce extraction bias.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.

The biannual administration method of inclisiran sets it apart from daily oral statins or frequent PCSK9 monoclonal antibody injections because it provides advantages for patient adherence and convenience.

“The biannual administration method of this medication sets it apart from daily oral statins or frequent PCSK9 monoclonal antibody injections because it provides advantages for patient adherence and convenience.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Disagreements in risk-of-bias domain ratings were resolved through discussion, and unresolved differences were adjudicated by a third reviewer.

“Disagreements in domain ratings were resolved through discussion, and unresolved differences were adjudicated by a third reviewer to minimize subjective assessment bias.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Data extraction was performed independently by two reviewers, and all extracted entries were cross verified.

“Data extraction was performed independently by two reviewers, and all extracted entries were cross verified.”

Probably not a substantial claim: may not pass S3 (load-bearing).

This systematic review and meta-analysis was not prospectively registered in PROSPERO.

“This systematic review and meta-analysis was not prospectively registered in PROSPERO.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Subgroup analysis and sensitivity tests were performed to identify different sources of variability.

“The researchers performed subgroup analysis and sensitivity tests to identify different sources of variability.”

May combine two claims.

Inclisiran provides beneficial lipid effects beyond lowering LDL-C, making it a valuable drug for cardiovascular risk management.

“Inclisiran provides beneficial lipid effects beyond lowering LDL-C which makes it a valuable drug for cardiovascular risk management.”

• AssumptionRests on an assumption: Reducing LDL-C levels reduces cardiovascular risk.

Classified as probably not a substantial claim. May combine two claims.

Searches were updated through December 31, 2024, and trials published after this date were not eligible for inclusion in the present pooled analyses.

“Searches were updated through December 31, 2024; trials published after this date (for example VICTORION-Difference, published Aug 30, 2025) were therefore not eligible for inclusion in the present pooled analyses but are discussed in the Introduction and Discussion as new evidence emerging after our cutoff [35].”

May combine two claims.

These results confirm the robustness and stability of the pooled effect estimate, suggesting that the inclusion or exclusion of the HoFH cohort does not materially alter the overall interpretation of inclisiran's efficacy across diverse patient groups.

“These results confirm the robustness and stability of the pooled effect estimate, suggesting that the inclusion or exclusion of the HoFH cohort does not materially alter the overall interpretation of inclisiran’s efficacy across diverse patient groups.”

May combine two claims.

The primary contributors to between-study heterogeneity were differences in untreated baseline LDL-C concentrations, phenotype-specific responses (ASCVD, HeFH, HoFH), and variability in background statin therapy, all of which are biologically plausible modifiers of inclisiran's LDL-C-lowering effect.

“The primary contributors to between-study heterogeneity were differences in untreated baseline LDL-C concentrations, phenotype-specific responses (ASCVD, HeFH, HoFH), and variability in background statin therapy, all of which are biologically plausible modifiers of inclisiran’s LDL-C–lowering effect.”

May combine two claims.

Long-term treatment with inclisiran benefits from its pharmacological durability, enabling better patient compliance and potentially improved long-term health results compared with PCSK9 monoclonal antibodies that require frequent dosing.

“Long-term treatment with inclisiran benefits from its pharmacological durability which enables better patient compliance and potentially improved long-term health results compared to monoclonal antibodies that neutralize PCSK9 and need frequent dosing.”

May combine two claims.

The study results showed an even distribution of data points surrounding the central effect measurement, which indicated minimal bias in publication.

“The study results showed an even distribution of data points surrounding the central effect measurement which indicated minimal bias in publication.”

May combine two claims.

These findings show that inclisiran has no adverse immunological effects and remains suitable for extended treatment periods.

“These findings show that inclisiran has no adverse immunological effects and remains suitable for extended treatment periods.”

Classified as probably not a substantial claim.

The researchers performed sensitivity analyses to verify the stability of the combined effect.

“The researchers performed sensitivity analyses to verify the stability of the combined effect.”

May combine two claims.

The systematic search was updated through December 2024, thereby incorporating the most recent and larger randomized controlled trials that were not available in earlier reviews with cut-offs between 2022 and 2024.

“First, our systematic search was updated through December 2024, thereby incorporating the most recent and larger randomized controlled trials, that were not available in earlier reviews with cut-offs between 2022 and 2024.”

May combine two claims.

The reductions in non-HDL-C and apoB closely followed the LDL-C changes and indicated widespread decreases in dangerous lipid particles.

“The reductions in these lipid markers closely followed the LDL-C changes and indicated widespread decreases in dangerous lipid particles.”

May combine two claims.

These results demonstrate that inclisiran is well tolerated, with an overall safety profile comparable to placebo or standard therapy.

“These results demonstrate that inclisiran is well tolerated, with an overall safety profile comparable to placebo or standard therapy.”

May combine two claims.

The drug's sustained LDL-C lowering effect stems from PCSK9 suppression and validates its pharmacodynamic action.

“The drug’s sustained LDL-C lowering effect stems from this suppression and validates its pharmacodynamic action.”

May combine two claims.

The therapeutic effect of inclisiran remains stable after two doses per year, making it stand apart from other lipid treatments and solving two main problems that affect chronic lipid management patients.

“The therapeutic effect of Inclisiran remains stable after two doses per year making it stand apart from other lipid treatments and solves two main problems that affect chronic lipid management patients.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

The distinct patient phenotype most likely accounts for the outlier result because it frequently presents lipid profiles that are difficult to treat with maximum medical therapy.

“The distinct patient phenotype most likely accounts for this result because it frequently presents lipid profiles that are difficult to treat with maximum medical therapy.”

May combine two claims.

The pharmacodynamic effects of inclisiran lead to an extended suppression of plasma PCSK9 levels, which directly correlates with significant LDL-C reduction.

“The pharmacodynamic effects of Inclisiran lead to an extended suppression of plasma PCSK9 levels which directly correlates with significant LDL-C reduction [71].”

• cites [71] Gosselin NH, Schuck VJ, Barriere O, Kulmatycki K, Margolskee A, Smith P, He Y. Translational population-pharmacodynamic modeling of a novel long‐acting SiRNA therapy, inclisiran, for the treatment of hypercholesterolemia. Clin Pharmacol Ther. 2023;113(2):328–38. sourceNot checked — no full text of the source

May combine two claims.

Through intracellular PCSK9 reduction, inclisiran enhances liver cell LDL receptor recycling, which results in higher receptor density and improved removal of blood LDL particles.

“Through intracellular PCSK9 reduction Inclisiran enhances liver cell LDL receptor recycling which results in higher receptor density and improved removal of blood LDL particles [9, 67].”

• cites [9] Liu S-s, Yu T, Qiao Y-f, Gu S-x. Chai X-l. Research on hepatocyte regulation of PCSK9-LDLR and its related drug targets. Chin J Integr Med. 2024;30(7):664–72. sourceNot checked — no full text of the source
• cites [67] Wang Z, Chen X, Liu J, Wang Y, Zhang S. Inclisiran inhibits oxidized low-density lipoprotein-induced foam cell formation in Raw264. 7 macrophages via activating the PPARγ pathway. Autoimmunity. 2022;55(4):223–32. sourceNot checked — no full text of the source

May combine two claims.

The study used a large pool of high-quality randomized data to provide a complete assessment of inclisiran safety and effectiveness.

“We used a big pool of high-quality randomized data to provide a complete assessment of Inclisiran safety and effectiveness.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.

The less frequent dosing of inclisiran might make up for its lower potency since it enhances patient adherence in the long term.

“The less frequent dosing of Inclisiran might make up for its lower potency since it enhances patient adherence in the long term.”

May combine two claims.

The dual aspects of PCSK9 suppression and twice-yearly treatment schedule make inclisiran effective while creating better conditions for patients to adhere to their treatments.

“The dual aspects of PCSK9 suppression and twice-yearly treatment schedule make Inclisiran effective while creating better conditions for patients to adhere to their treatments [47, 72].”

• cites [47] Barkas F, Ray K. An update on inclisiran for the treatment of elevated LDL cholesterol. Expert Opin Pharmacother. 2024;25(4):349–58. sourceNot checked — no full text of the source
• cites [72] Mansoor T, Rao BH, Gupta K, Parikh SS, Abramov D, Mehta A, et al. Inclisiran as a SiRNA inhibitor of proprotein convertase Subtilisin/Kexin type 9 (PCSK9); Past, Present, and future. Am J Cardiovasc Drugs. 2025;25(3):293–306. sourceNot checked — no full text of the source

May combine two claims.

Inclisiran enables lipid management escalation without the typical safety limitations of present-day lipid therapies, allowing patients needing effective LDL-C reduction to receive treatment in clinical practice.

“The results demonstrate that Inclisiran enables lipid management escalation without the typical safety limitations of present-day lipid therapies so patients who need effective LDL-C reduction can receive treatment in clinical practice.”

Classified as probably not a substantial claim.